Header Logo

Connection

JIUN-KAE JACK LEE to Disease-Free Survival

Back to Details
This is a "connection" page, showing publications JIUN-KAE JACK LEE has written about Disease-Free Survival.
JIUN-KAE JACK LEE
Connection Strength
0.423
Disease-Free Survival
  1. Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res. 2014 Apr 01; 20(7):1946-54.
    View in: PubMed
    Score: 0.049
  2. Mortality in the randomized, controlled lung intergroup trial of isotretinoin. Cancer Prev Res (Phila). 2010 Jun; 3(6):738-44.
    View in: PubMed
    Score: 0.038
  3. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res. 2000 May; 6(5):1702-10.
    View in: PubMed
    Score: 0.019
  4. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res. 1995 Oct; 1(10):1103-10.
    View in: PubMed
    Score: 0.014
  5. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):317-24.
    View in: PubMed
    Score: 0.013
  6. Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. J Thorac Oncol. 2014 May; 9(5):675-84.
    View in: PubMed
    Score: 0.012
  7. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2014 May; 15(3):197-201.
    View in: PubMed
    Score: 0.012
  8. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75.
    View in: PubMed
    Score: 0.012
  9. Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. Ann Oncol. 2013 Oct; 24(10):2534-2542.
    View in: PubMed
    Score: 0.012
  10. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61.
    View in: PubMed
    Score: 0.012
  11. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget. 2013 May; 4(5):705-14.
    View in: PubMed
    Score: 0.012
  12. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. Mol Cancer Ther. 2013 Jun; 12(6):1112-21.
    View in: PubMed
    Score: 0.012
  13. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75.
    View in: PubMed
    Score: 0.011
  14. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013 Jan 01; 73(1):276-84.
    View in: PubMed
    Score: 0.011
  15. Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20; 30(27):3345-52.
    View in: PubMed
    Score: 0.011
  16. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res. 2012 Jul 01; 18(13):3705-13.
    View in: PubMed
    Score: 0.011
  17. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.
    View in: PubMed
    Score: 0.011
  18. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
    View in: PubMed
    Score: 0.011
  19. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012 Jun 01; 118(11):2889-99.
    View in: PubMed
    Score: 0.010
  20. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer. 2012 May 01; 118(9):2454-65.
    View in: PubMed
    Score: 0.010
  21. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol. 2012 Jan; 23(1):78-85.
    View in: PubMed
    Score: 0.010
  22. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst. 2010 Jun 16; 102(12):859-65.
    View in: PubMed
    Score: 0.010
  23. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer. 2010 May 15; 116(10):2401-8.
    View in: PubMed
    Score: 0.009
  24. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res. 2010 Feb 15; 16(4):1289-97.
    View in: PubMed
    Score: 0.009
  25. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010 Jan 10; 28(2):193-201.
    View in: PubMed
    Score: 0.009
  26. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol. 2009 Feb 01; 27(4):599-604.
    View in: PubMed
    Score: 0.009
  27. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9.
    View in: PubMed
    Score: 0.007
  28. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006 Apr 05; 98(7):441-50.
    View in: PubMed
    Score: 0.007
  29. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope. 2005 Sep; 115(9):1561-7.
    View in: PubMed
    Score: 0.007
  30. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3230-7.
    View in: PubMed
    Score: 0.006
  31. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control. 2003 Mar; 14(2):131-8.
    View in: PubMed
    Score: 0.006
  32. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2001 Apr 18; 93(8):605-18.
    View in: PubMed
    Score: 0.005
  33. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000 Dec 01; 18(23):3904-11.
    View in: PubMed
    Score: 0.005
  34. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res. 2000 Mar; 6(3):790-7.
    View in: PubMed
    Score: 0.005
  35. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res. 1998 Dec; 8(6):549-56.
    View in: PubMed
    Score: 0.004
  36. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998 Jun; 16(6):2253-60.
    View in: PubMed
    Score: 0.004
  37. Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg. 1995 Dec; 60(6):1563-70; discussion 1570-2.
    View in: PubMed
    Score: 0.003
  38. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol. 1995 Sep; 13(9):2361-8.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.